Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Pharma
The Oral GLP-1 Tracker: Scripts bounce back from holiday lull
Fierce Pharma's weekly Oral GLP-1 Tracker monitors prescription trends for Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo.
Angus Liu
,
Kevin Dunleavy
,
Fraiser Kansteiner
,
Donavyn Coffey
Sep 25, 2026 2:00pm
Eli Lilly blasted for ‘emotive’ language in GLP-1 press release
Sep 25, 2026 9:01am
Lilly captures 70% of surging Medicare GLP-1 market, CEO says
Sep 23, 2026 10:55am
Novo testing smaller doses of Wegovy pill in phase 3 study
Aug 20, 2026 8:51am
Danish politicians call out Lilly campaign
Aug 16, 2026 8:25am
Obesity not a winner-takes-all game, Novo CEO says: Reuters
Aug 13, 2026 11:33am
